	Basic Elements of Informed Consent (new elements in the 2018 rule in bold)	Citation
0 0 0	Statement that study involves research, Explanation of the purposes of the research and the expected duration of the subjects' participation, A description of the procedures to be followed, and Identification of any procedures that are experimental	116(b)(1)
0	Description of any reasonably foreseeable risks or discomforts to the subject	116(b)(2)
0	Description of any benefits to the subject or to others that may reasonably be expected from the research	116(b)(3)
0	Disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject	116(b)(4)
0	Statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained	116(b)(5)
0	For research involving more than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained	116(b)(6)
0	Explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a research-related injury to the subject	116(b)(7)
0	Statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled; and	116(b)(8)
0	Statement that identifiers might be removed from the identifiable private information or identifiable biospecimens and that, after such removal, the information or biospecimens could be used for future research studies or distributed to another investigator for future research studies without additional informed consent from the subject or the LAR, if this might be a possibility - OR - Statement that the subject's information or biospecimens collected as part of the research, even if identifiers are removed, will not be used or distributed for future research studies	116(b)(9) (i) and (ii)
	Additional Elements of Informed Consent (as appropriate to the research) (new elements in the 2018 rule in bold)	Citation
0	Statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable	116(c)(1)
0	Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent	116(c)(2)
0	Any additional costs to the subject that may result from participation in the research	116(c)(3)
0	Consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject	116(c)(4)
0	Statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject	116(c)(5)
0	Approximate number of subjects involved in the study	116(c)(6)
0	Statement that the subject's biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subject will or will not share in this commercial profit	116(c)(7)
0	Statement regarding whether clinically relevant research results, including individual research results, will be disclosed to subjects, and if so, under what conditions; and	116(c)(8)
0	For research involving biospecimens, whether the research will (if known) or might include whole genome sequencing (i.e., sequencing of a human germline or somatic specimen with the intent to generate the genome or exome sequence of that specimen)  Flements of Informed Consent/IRB-HSRS/rev, 12 14 2017	116(c)(9)